Article

Supplemental Information

International Statistical Classification of Diseases G020* in viral diseases and Related Health Problems, A852 Arthropod-borne viral classified elsewhere , unspecified Tenth Revision, Canada Codes Used to Identify Potential G021* Meningitis in mycoses A858 Other specified viral Cases G028* Meningitis in other specified encephalitis infectious and parasitic diseases A86 Unspecified classified elsewhere A922 Venezuelan equine fever A170 G030 Nonpyogenic meningitis A923 West Nile virus A203 Plague meningitis G031 Chronic meningitis B004 A321 Listerial meningitis and G032 Benign recurrent meningitis B011 Varicella encephalitis (Mollaret) B020 Zoster encephalitis A390 Meningococcal meningitis G038 Meningitis due to other A870 Enteroviral meningitis specified causes B050 Measles complicated by encephalitis A871 Adenoviral meningitis G039 Meningitis, unspecified B262 encephalitis A872 Lymphocytic choriomeningitis A811 Subacute sclerosing panencephalitis B582 Toxoplasma A878 Other meningoencephalitis A830 Japanese encephalitis A879 Viral meningitis, unspecified G040 Acute disseminated A831 Western equine encephalitis B003 encephalitis A832 Eastern equine encephalitis B010 Varicella meningitis G042 Bacterial meningoencephalitis A833 St Louis encephalitis B021 Zoster meningitis and meningomyelitis, not elsewhere A834 Australian encephalitis classified B051 Measles complicated by meningitis A835 California encephalitis G048 Other encephalitis, and B261 Mumps meningitis A838 Other mosquito-borne viral G049 Encephalitis, myelitis and B375 Candidal meningitis encephalitis encephalomyelitis, unspecified B384 Coccidioidomycosis meningitis A839 Mosquito-borne viral encephalitis, unspecified G050* Encephalitis, myelitis and G000 A840 Far Eastern tick-borne encephalomyelitis in bacterial G001 Pneumococcal meningitis encephalitis (Russian spring-summer diseases classified elsewhere G002 Streptococcal meningitis encephalitis) G05.1* Encephalitis, myelitis and G003 Staphylococcal meningitis A841 Central European tick-borne encephalomyelitis in viral diseases classified elsewhere G008 Other bacterial meningitis encephalitis G052* Encephalitis, myelitis and G009 Bacterial meningitis, A848 Other tick-borne viral encephalitis encephalomyelitis in other infectious unspecified and parasitic diseases classified G00 Bacterial meningitis, not A849 Tick-borne viral encephalitis, elsewhere unspecified elsewhere classified G058* Encephalitis, myelitis and G01 Meningitis in bacterial diseases A850 Enteroviral encephalitis encephalomyelitis in other diseases classified elsewhere A851 Adenoviral encephalitis classified elsewhere

PEDIATRICS Volume 140, Number 1, July 2017 SI1 SUPPLEMENTAL TABLE 6 Clinical, Laboratory, and Radiographic Predictors of Adverse Outcomes in Infants With Meningitis (Subgroup of Children Admitted From Home, n = 63) Outcome at Last Follow-up Prognostic Marker, n (%) RR (95% CI) P in Hospital (21) No Seizures (42) No apparent sequelae 0 18 (43) — <.001 Hearing loss 1 (4.8) 1 (2.4) 2.0 (0.13–30) 1.0 Vision problem 1 (4.8) 0 — .33 Motor problem (spasticity, paresis) 8 (38) 1 (2.4) 16 (2.1–120) <.001 Developmental delay 4 (19) 3 (7.1) 2.7 (0.66–11) .21 Death 4 (19) 0 — .010 CSF protein >5 g/L (6)a CSF protein ≤5 g/L (44)a No apparent sequelae 0 16 (36) — .16 Hearing loss 1 (17) 1 (2.3) 7.3 (0.52–100) .23 Vision problem 0 1 (2.3) — 1.0 Motor problem (spasticity, paresis) 3 (50) 6 (14) 3.7 (1.2–11) .063 Developmental delay 1 (17) 2 (4.5) 3.7 (0.39–35) .32 Death 1 (17) 1 (2.3) 7.3 (0.52–100) .23 on neuroimaging (10) No hydrocephalus (53) No apparent sequelae 0 18 (34) — .050 Hearing loss 1 (10) 1 (1.9) 5.3 (0.36–78) .29 Vision problem 0 1 (1.9) — 1.0 Motor problem (spasticity, paresis) 4 (40) 5 (9.4) 4.2 (1.4–13) .029 Developmental delay 2 (20) 5 (9.4) 2.1 (0.48–9.4) .31 Death 1 (10) 3 (5.7) 1.7 (0.20–15) .51 Numbers in table represent n (%) or RR (95% CI). RR, relative risk. —, not applicable. a Data missing for CSF protein for 13 patients (n = 50).

SUPPLEMENTAL TABLE 7 Clinical, Laboratory, and Radiographic Predictors of Adverse Outcomes in Infants With Meningitis (Subgroup of Children Remaining in Hospital Since Birth, n = 50) Outcome at Last Follow-up Prognostic Marker, n (%) RR (95% CI) P Seizures in Hospital (20) No Seizures (30) No apparent sequelae 4 (20) 7 (23) 0.86 (0.29–2.6) 1.0 Hearing loss 3 (15) 0 — .058 Vision problem 0 0 — 1.0 Motor problem (spasticity, paresis) 4 (20) 6 (20) 1.0 (0.32–3.1) 1.0 Developmental delay 4 (20) 1 (3.3) 6.0 (0.72–50) .14 Death 3 (15) 1 (3.3) 4.5 (0.50–40) .29 CSF protein >5 g/L (n = 11)a CSF protein ≤5 g/L (n = 28)a No apparent sequelae 2 (18) 6 (21) 0.85 (0.20–3.6) 1.0 Hearing loss 1 (9.1) 0 — .28 Vision problem 0 0 — 1.0 Motor problem (spasticity, paresis) 3 (27) 3 (11) 2.5 (0.60–11) .32 Developmental delay 2 (18) 1 (3.6) 5.1 (0.51–51) .19 Death 1 (9.1) 2 (7.1) 1.3 (0.13–13) 1.0 Hydrocephalus on neuroimaging (14) No hydrocephalus (36) No apparent sequelae 3 (21) 8 (22) 0.96 (0.30–3.1) 1.0 Hearing loss 2 (14) 1 (2.8) 5.1 (0.51–52) .19 Vision problem 0 0 — 1.0 Motor problem (spasticity, paresis) 6 (43) 4 (11) 3.9 (1.3–12) .020 Developmental delay 1 (7.1) 4 (11) 0.64 (0.079–5.3) 1.0 Death 1 (7.1) 3 (8.3) 0.85 (0.097–7.6) 1.0 Numbers in table represent n (%) or RR (95% CI). RR, relative risk. —, not applicable. a Data missing for CSF protein for 11 patients (n = 39).

SI2 Ouchenir et al